| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2155535 | Pathology - Research and Practice | 2014 | 5 Pages |
Abstract
C-kit expression is found in the majority of cpRCC and RO, but these tumors do not harbor the usual c-kit activating mutations. This may have implications for the use of tyrosine kinase inhibitors in patients with advanced cpRCC and c-kit expression.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Annette Zimpfer, Stephanie Janke, Maja Hühns, Björn Schneider, Günther Kundt, Heike Zettl, Ergin Kilic, Matthias Maruschke, Oliver W. Hakenberg, Andreas Erbersdobler,